A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

Inclusion Criteria:

- Has demonstrated tolerability to test doses of oral aripiprazole during screening; OR
has a history of tolerated use of aripiprazole

- Has a diagnosis of schizophrenia

- Is clinically stable

- Has received at least 3 doses of risperidone long acting injection (Risperdal Consta)
or paliperidone palmitate (Invega Sustenna) prior to screening.

- Has no antipsychotic medication regimen change for 4 weeks prior to Day 1

- Agreed to abide by the contraceptive requirements o the protocol

- Resides in a stable living situation

- Additional criteria may apply

Exclusion Criteria:

- Is currently pregnant or breastfeeding, or is planning to become pregnant during the
study

- Has received Invega Trinza, aripiprazole lauroxil, or IM depot aripiprazole within 6
months of screening

- Has participated in a clinical trial involving any investigational product within the
past 3 months, or is currently participating in a clinical trial involving an
investigational product

- Has a positive urine drug test for illicit use of amphetamines, barbiturates, cocaine,
methadone, opiates, phencyclidine at screening

- Additional criteria may apply